Tom Kline named co-liaison counsel for Risperdal cases

Tom Kline has been named co-liaison counsel by the Court of Common Pleas for Philadelphia for the coordinated litigation involving the drug Risperdal. The anti-psychotic pharmaceutical has been linked to abnormal breast growth in males, including children, adolescents and adults, a condition called gynocomastia. The coordinated litigation in Philadelphia includes about 400 cases. Kline & Specter is serving as lead counsel for a large majority of those cases, joining with the law firm Sheller, PC, which pioneered the Risperdal litigation. Tom Kline is slated to try the first Risperdal case scheduled for July 2014 and involving an autistic child who suffers gynecomastia after using Risperdal. Learn more about Risperdal lawsuits.